Pancreatic acinar cell carcinoma––literature review and case report of a 56-year-old man presenting with abdominal pain

Fontenot, Jake; Spieler, Bradley; Hudson, Catherine; Boulmay, Brian C.

doi:10.1016/j.radcr.2019.10.009

Cited by 10 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the treatment regimens used are the same as those used for PDAC or colorectal cancer [36]. Simultaneous removal of double primary carcinomas should be attempted, radiotherapy and chemotherapy should also be considered for patients who need adjuvant treatment decided by both disease stage [37]. If it is necessary to adjuvant treatment, try to choose an antineoplastic therapy that takes both into account.…”

Section: Discussionmentioning

confidence: 99%

Synchronous Pancreatic Acinar Cell Adenocarcinoma and Gastric Adenocarcinoma: a Case Report and Literature Review

Fang

Liang

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Multiple primary malignant tumors are two or more malignancies in an individual without any relationship between the neoplasms. In recent years, increasing number of cases have been reported. However, Synchronous double primary gastric cancer and pancreatic acinar cell carcinoma are relatively rare to be reported. Further, most pancreatic tumors are consistent with pancreatic ductal adenocarcinomas, and other histologies are rare. We present the first case of synchronous pancreatic acinar cell adenocarcinoma and gastric adenocarcinoma.Case presentation: A 69-year-old man came to our department with a history of vomiting, epigastric pain, and weight loss. Imaging revealed space-occupying lesions in the stomach and the tail of the pancreas, respectively. The patient underwent laparoscopic radical gastrectomy and pancreatectomy simultaneously. The pathologies of surgical specimens were completely different: the resected gastric specimen was a moderate to poorly differentiated adenocarcinoma, whereas the pancreatic tumor was consistent with acinar cell carcinoma. The patient was treated with six cycles of oxaliplatin and S-1 chemotherapy. As of March 2021, the patient was healthy without any recurrence or metastasis. After reviewing lots of literatures on simultaneous pancreatic and gastric cancers at home and abroad, we discuss the clinical characteristics of these rare synchronous double cancers. Most of the cases had undergone surgery and adjuvant chemotherapy, and all of the cases were pathologically confirmed by postoperative specimen. Conclusions: Synchronous pancreatic acinar cell and gastric adenocarcinoma can occur and should be considered when tumors are found in these organs.

show abstract

Section: Discussionmentioning

confidence: 99%

Synchronous Pancreatic Acinar Cell Adenocarcinoma and Gastric Adenocarcinoma: a Case Report and Literature Review

Fang

Liang

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The response to platinum-containing regimens was 40%, and the overall survival tended to be better in patients who had received a platinum-containing regimen[ 38 ]. Simultaneous removal of concomitant primary carcinomas should be attempted; radiotherapy and chemotherapy should also be considered for patients who need adjuvant treatment decided by both disease stages[ 39 ]. If adjuvant treatment is required, the physician should select an antineoplastic therapy that considers both cancers.…”

Section: Discussionmentioning

confidence: 99%

Synchronous concomitant pancreatic acinar cell carcin and gastric adenocarcinoma: A case report and review of literature

Fang¹,

Liang²,

Wang³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Multiple primary malignant tumors are two or more malignancies in an individual without any relationship between the neoplasms. In recent years, an increasing number of cases have been reported. However, concomitant primary gastric and pancreatic cancer reported a relatively small incidence, involving no pancreatic acinar cell carcinoma reports. Here, we present the first case of concomitant pancreatic acinar cell carcinoma and gastric adenocarcinoma. CASE SUMMARY A 69-year-old male presented to our department with a history of vomiting, epigastric pain, and weight loss. Imaging revealed space-occupying lesions in the stomach and the tail of the pancreas, respectively. The patient underwent laparoscopic radical gastrectomy and pancreatectomy simultaneously. The pathologies of surgical specimens were completely different: The resected gastric specimen was moderate to poorly differentiated adenocarcinoma, whereas the pancreatic tumor was consistent with acinar cell carcinoma. The patient was treated with six cycles of oxaliplatin and S-1 chemotherapy. As of March 2021, the patient was healthy without any recurrence or metastasis. After thoroughly reviewing the literature on simultaneous pancreatic and gastric cancers at home and abroad, we discussed the clinical characteristics of these rare synchronous double cancers. Most of the cases had undergone surgery and adjuvant chemotherapy, and all of the cases were pathologically confirmed by the postoperative specimen. CONCLUSION Synchronous pancreatic acinar cells and gastric adenocarcinoma can occur and should be considered when tumors are found in these organs.

show abstract

“…2CR/4PR/1SD Nishimizu T [36] / Fukui H [37] / Hatata T [38] Miyagawa K [39] /Toda H [31] / Brunetti O [23] 2010/2011 2016/2018 FOLFOX/CAPEOX 4PR/3SD/1PD Yoo C [15] / Fontenot J [40] / Morales M [41] Brunetti O [23] /Kruger S [30] /Jordan E [42] 2013/2016-2018…”

Section: Gemcitabinebased Ag 1sd/2pdmentioning

confidence: 99%

Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literatures

Xu¹,

Guan²,

Lu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Pancreatic acinar cell carcinoma (PACC) is rare and its appropriate treatment remains unknown dued to limited and selection-biased dataMethods: The data on clinicopathologic characteristics, molecular alteration, treatment and survival of patients diagnosed as PACC in Sun Yat-sen university cancer center from 2005 to 2020 were collected. We explored the optimal treatment by co-analyzing our results and published literatures.Results: 22 PACC patients were enrolled. 8/17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n=3) had better mDFS than those with gemcitabine-based regimen (n=5) (unreached vs. 27 months). 8 metastatic patients received 1st-line chemotherapy. 4/5 patients with FOLFIRINOX regimen achieved partial response (PR) and 3 patients with AG (albumin paclitaxel+gemcitabine) regimen got progressive disease (PD). 4 patients received 2nd-line chemotherapy. 2 patients with FOLFIRINOX regimen achieved PR while 2 patients with AG regimen got PD. One patient who had responded to 1st-line FOLFIRINOX regimen received Olaparib as maintenance treatment for 5 months with good tolerance. 31 published literatures and a total of 86 cases were included in the co-analysis. Objective response rate of 1st-line fluoropyrimidine-based regimen (n=47) was higher than that of gemcitabine-based regimen (n=39) (59.6% vs.15.3%, P<0.001). 8/11 patients treated with FOLFIRINOX regimen achieved PR. Conclusions: The benefit of adjuvant chemotherapy remained unclear; however, fluoropyrimidine-based chemotherapy deserves attention. For metastatic patients, fluorouracil-based regimen such as FOLFIRINOX is preferred, and maintenance treatment of PARP inhibitors after effective platinum-containing treatment for BRAC mutation patients is worthy of exploration.

show abstract

Pancreatic acinar cell carcinoma––literature review and case report of a 56-year-old man presenting with abdominal pain

Cited by 10 publications

References 14 publications

Synchronous Pancreatic Acinar Cell Adenocarcinoma and Gastric Adenocarcinoma: a Case Report and Literature Review

Synchronous Pancreatic Acinar Cell Adenocarcinoma and Gastric Adenocarcinoma: a Case Report and Literature Review

Synchronous concomitant pancreatic acinar cell carcin and gastric adenocarcinoma: A case report and review of literature

Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literatures

Contact Info

Product

Resources

About